Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Vyant Bio, Inc. (CGIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/16/2022 8-K Quarterly results
08/16/2021 8-K Quarterly results
Docs: "Vyant Bio, Inc. Consolidated Balance Sheets June 30, December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $ 26,485 $ 792 Trade accounts and other receivables 1,261 357 Inventory 407 415 Patent held for sale 30 - Prepaid expenses and other current assets 1,890 223 Total current assets 30,073 1,787 Non-current assets: Fixed assets, net 1,654 1,031 Operating lease right-to-use assets, net 1,068 1,095 Intangible assets, net 9,262 - Goodwill 21,703 - Long-term prepaid expenses and other assets 1,641 136 Total non-current assets 35,328 2,262 Total Assets $ 65,401 $ 4,049 Liabilities, Temporary Equity and Stockholders’ Equity Current liabilities: Accounts payable $ 1,016 $ 1,300 Accrued expenses 1,246 162 Deferred revenue 1,416 92 Obligations under operating leases, current po..."
05/17/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Cancer Genetics Reports Third Quarter 2020 Financial Results"
08/14/2020 8-K Quarterly results
06/24/2020 8-K Quarterly results
Docs: "Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates"
06/01/2020 8-K Quarterly results
Docs: "Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates"
11/20/2019 8-K Quarterly results
Docs: "Cancer Genetics Reports Third Quarter 2019 Financial Results and Provides Strategic Business Update"
08/20/2019 8-K Quarterly results
Docs: "Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update"
05/20/2019 8-K Quarterly results
Docs: "Cancer Genetics Reports First Quarter 2019 Financial Results and Provides Strategic Business Update RUTHERFORD, N.J., May 20, 2019 — Cancer Genetics, Inc. , a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics, molecular markers and data solutions, today announced financial and operating results for the first quarter ended March 31, 2019. RECENT OPERATIONAL HIGHLIGHTS ● Raised total net proceeds of $5.4 million in January through two common stock offerings of 28.55 million common shares. In connection with the two capital raises, the Company issued warrants for 2 million shares. ● Reduced overall combined quarterly cost of revenue and operating expenses by $2.9 million compared to the first quarter of 2018. ● Revenue for the..."
04/16/2019 8-K Quarterly results
Docs: "Cancer Genetics, Inc. and Subsidiaries Consolidated Balance Sheets December 31, 2018 2017 ASSETS CURRENT ASSETS Cash and cash equivalents $ 161 $ 9,541 Accounts receivable, net of allowance for doubtful accounts of 2018 $3,462; 2017 $6,539 7,038 10,958 Other current assets 2,148 2,707 Total current assets 9,347 23,206 FIXED ASSETS, net of accumulated depreciation 4,056 5,550 OTHER ASSETS Restricted cash 350 350 Patents and other intangible assets, net of accumulated amortization 4,004 4,478 Investment in joint venture 92 246 Goodwill 17,257 17,992 Other 300 399 Total other assets 22,003 23,465 Total Assets $ 35,406 $ 52,221 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued expenses $ 13,067 $ 8,715 Obligations under capital leases, current portion 330 27..."
11/19/2018 8-K Quarterly results
Docs: "Cancer Genetics Reports Third Quarter 2018 Financial Results and Provides Strategic Business Updates"
08/14/2018 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics Reports Second Quarter 2018 Financial Results and Provides Strategic Business Updates",
"— Slide presentation for Q2 2018 earnings call"
05/15/2018 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates"
04/02/2018 8-K Investor presentation, Quarterly results
Docs: "—",
"—"
11/09/2017 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics Reports Record Third Quarter 2017 Revenue and 134% Increase in Contracted Bookings from Major Biotech and Pharmaceutical Companies",
"Q3 2017 Earnings Report & Company Updates Thursday - November 9, 2017 08:30am Eastern CEO: Panna Sharma webcast link: http://public.viavid.com/player/index.php?id=127177 Forward-Looking Statements These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact should also be considered to be forward-looking ..."
08/14/2017 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics, Inc. Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise",
"Cancer Genetics Announces Transformative and Accretive Acquisition of vivoPharm, a Global Oncology & Immuno-Oncology Discovery Services Company ▪ Acquisition Strengthens CGI’s Bench-to-Bedside Capabilities and Bolsters Growth with Global Customer Base of Biopharma Partners ▪ Expands Discovery and Early Development Revenue Base with Highly Complementary Biotechnology and Pharmaceutical Customers, Especially in Europe and Asia-Pacific ▪ Acquisition is Expected to be Immediately Accretive Based on vivoPharm’s History of Profitability ▪ Increases Immuno-Oncology and Pharmacology Capabilities Adding Over 55 New Projects with Over 30 in Immuno-Oncology ▪ Transforms Operations & Value Proposition by Increasing Drug Identification, Drug Rescue and Drug Repurposing Cap...",
"– Slide presentation for Q2 2017 earnings call"
05/11/2017 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics, Inc. Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability ▪ Revenue increased to $7.0 million in Q1 2017, up 15% compared to Q1 2016 on strong organic growth ▪ Test volumes increased 19% year-over-year to 12,310 ▪ Gross profit margin was 40%, up from 32% for Q1 2016 ▪ Reduced total operating expenses 21% to $5.6 million in Q1 2017, down from $7.1 million in Q1 2016 ▪ Reduced first quarter loss from operations by 46% compared to Q1 2016, improving pathway to profitability ▪ Strengthened balance sheet with exercise of warrants, adding $1.8 million in cash ▪ Conference call begins at 9:00 a.m. Eastern, Friday, May 12, 2017",
"– Slide presentation for Q1 2017 earnings call"
03/23/2017 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
05/10/2016 8-K Form 8-K - Current report
03/10/2016 8-K Form 8-K - Current report
11/10/2015 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics, Inc. Announces Strong Third Quarter and Year-to Date 2015 Results",
"– Slide presentation for Q3 2015 earnings call"
08/11/2015 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics Announces Strong Second Quarter 2015 Results",
"– Slide presentation for Q2 2015 earnings call",
"Press release",
"– Slide presentation of investor frequently asked questions"
05/12/2015 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics Announces Strong First Quarter 2015 Results • Company Reports Record Quarterly Revenues of $4.4 million, an Increase of 206% vs. First Quarter 2014 • Next-Generation Sequencing Panels Rapidly Progress into Usage by Both Clinical and Biopharma Customers • Cancer Genetics to Host Conference Call Today, Tuesday, May 12th, at 8:30am Eastern Time /5:30am Pacific",
"– Corporate presentation"
03/12/2015 8-K Investor presentation, Quarterly results
Docs: "Cancer Genetics Announces Record Fourth Quarter and Full-Year 2014 Revenue • Fourth Quarter Revenues up 118 Percent Year over Year to $4 million • Full-Year 2014 Revenue Increase up 54 Percent over 2013 to $10.2 Million • Cancer Genetics to Host Conference Call Today, Thursday March 12th at 8:30 am Eastern Time / 5:30 am Pacific Time",
"– Corporate Presentation"
11/10/2014 8-K Quarterly results
Docs: "EXHIBIT"
05/15/2014 8-K Quarterly results
Docs: "Cancer Genetics Enters Into Agreement to Acquire BioServe India, a Premier Genomics & Next Generation Sequencing Company, and Announces First Quarter 2014 Results",
"Cancer Genetics Inc. Announces Acquisition of Premier Genomics and Next Generation Sequencing Company, BioServe India"
11/13/2013 8-K Quarterly results
Docs: "Cancer Genetics, Inc. Announces Third Quarter Financial Results Test volume increased 71% year-over-year in the third quarter Revenue from commercial sales increased 67% year-over-year in the third quarter"
08/05/2013 8-K Form 8-K - Current report
05/15/2013 8-K Quarterly results
Docs: "Cancer Genetics Announces First Quarter 2013 Financial Results and Significant Business and Portfolio Progress First quarter revenue increased 46% YoY Clinical test volume increased 19% YoY Institutional client base grows to 42% of revenues DNA-Probe product manufacturing moved to India, reducing cost of goods RUTHERFORD, NJ, May 15, 2013 /Business Wire/ — Cancer Genetics, Inc. is an emerging leader in the diagnosis and disease management for the most complex and difficult-to-treat cancers, including hematologic, urogenital, and gynecological malignancies. CGI's focused portfolio of IP-protected and clinically validated genomic tests, CAP- and CLIA-certified reference laboratory, and suite of unique service offerings are ideally positioned to serve the needs of clinicians, pathologists an..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy